- -

Markov Models for Economic Evaluation in Osteoporosis Treatment

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Markov Models for Economic Evaluation in Osteoporosis Treatment

Mostrar el registro sencillo del ítem

Ficheros en el ítem

dc.contributor.author Osca Guadalajara, Marta es_ES
dc.contributor.author Díaz-Carnicero, Javier es_ES
dc.contributor.author González-De Julián, Silvia es_ES
dc.contributor.author Vivas-Consuelo, David es_ES
dc.date.accessioned 2022-09-30T18:06:25Z
dc.date.available 2022-09-30T18:06:25Z
dc.date.issued 2021-09 es_ES
dc.identifier.uri http://hdl.handle.net/10251/186777
dc.description.abstract [EN] Osteoporosis is frequent in elderly people, causing bone fractures and lowering their quality of life. The costs incurred by these fractures constitute a problem for public health. Markov chains were used to carry out an incremental cost-utility analysis of the four main drugs used in Spain to treat osteoporosis (alendronate, risedronate, denosumab and teriparatide). We considered 14 clinical transition states, from starting osteoporotic treatment at the age of 50 until death or the age of 100. Cost-effectiveness was measured by quality adjusted life years (QALYs). The values used in the Markov model were obtained from the literature. Teriparatide is the cost-effective alternative in the treatment of osteoporosis in patients with fractures from the age of 50, establishing a payment threshold of 20,000 EUR/QALY. However, it is the most expensive therapy, not appearing cost-effective in cases that do not present fracture and in ages over 80 years with fracture. Alendronate and denosumab therapies are presented as cost-effective osteoporosis treatment alternatives depending on the age of onset and duration of treatment. From the perspective of cost-effectiveness, establishing a payment threshold of 20,000 EUR/QALY, teriparatide is the cost-effective alternative in patients with fracture from the age of 50 to 70 years old in Spain. es_ES
dc.language Inglés es_ES
dc.publisher MDPI AG es_ES
dc.relation.ispartof Mathematics es_ES
dc.rights Reconocimiento (by) es_ES
dc.subject Markov chains es_ES
dc.subject Cost-utility es_ES
dc.subject QALY es_ES
dc.subject Osteoporosis es_ES
dc.subject.classification ECONOMIA APLICADA es_ES
dc.subject.classification ECONOMIA FINANCIERA Y CONTABILIDAD es_ES
dc.title Markov Models for Economic Evaluation in Osteoporosis Treatment es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.3390/math9182331 es_ES
dc.rights.accessRights Abierto es_ES
dc.contributor.affiliation Universitat Politècnica de València. Departamento de Economía y Ciencias Sociales - Departament d'Economia i Ciències Socials es_ES
dc.description.bibliographicCitation Osca Guadalajara, M.; Díaz-Carnicero, J.; González-De Julián, S.; Vivas-Consuelo, D. (2021). Markov Models for Economic Evaluation in Osteoporosis Treatment. Mathematics. 9(18):1-20. https://doi.org/10.3390/math9182331 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion https://doi.org/10.3390/math9182331 es_ES
dc.description.upvformatpinicio 1 es_ES
dc.description.upvformatpfin 20 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 9 es_ES
dc.description.issue 18 es_ES
dc.identifier.eissn 2227-7390 es_ES
dc.relation.pasarela S\446828 es_ES
dc.contributor.funder Universitat Politècnica de València es_ES
upv.costeAPC 872,85 es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem